Welcome to our dedicated page for Galapagos Nv news (Ticker: GLPG), a resource for investors and traders seeking the latest updates and insights on Galapagos Nv stock.
Galapagos NV (GLPG) generates a steady stream of news driven by its biotechnology programs in oncology, immunology, and related disease areas. As a company listed on Euronext and Nasdaq with operations in Europe and the United States, Galapagos frequently announces clinical collaborations, manufacturing agreements, and discovery partnerships that shape its pipeline of small molecules, biologics, CAR-T therapies, and other cell therapies.
News about Galapagos often covers developments in its oncology and cell therapy portfolio, including CAR-T programs in hematology-oncology and TCR T-cell therapy collaborations. Recent releases have highlighted decentralized manufacturing partnerships with organizations such as Landmark Bio and Excellos, aimed at producing CAR-T cell therapy candidates close to cancer treatment centers using Galapagos’ decentralized manufacturing platform. Updates on clinical proof-of-concept trials, such as those involving uza-cel in head and neck cancer, also feature prominently.
Investors and healthcare professionals can expect coverage of strategic discovery alliances, including agreements with BridGene Biosciences to discover small molecule drug candidates like a selective SMARCA2 PROTAC in precision oncology, and collaborations with Scipher Medicine for inflammatory bowel disease target discovery. Historical news items include portfolio decisions such as the discontinuation of the ziritaxestat IPF program and the sale of Fidelta, a contract research organization, to Selvita.
This news feed is a resource for tracking Galapagos’ clinical trial milestones, licensing and option agreements, manufacturing network expansion, and key R&D decisions. Users interested in GLPG can review past and recent announcements in one place and revisit the page regularly to follow new press releases and transaction updates as they are reported.
Excellos Inc., a cell therapy CDMO member of Blood Centers of America (BCA), has been selected to manufacture Galapagos' CAR-T cell therapy candidate, GLPG5101, for its FDA-cleared ATALANTA-1 clinical study in patients with relapsed/refractory non-Hodgkin lymphoma in the U.S. Excellos will provide end-to-end manufacturing at its new facility in San Diego, CA, using Galapagos' innovative, decentralized manufacturing platform.
This platform aims to address limitations in CAR-T cell therapy production, offering greater speed and scalability with a median vein-to-vein time of seven days. The collaboration is part of a strategic agreement between Galapagos' U.S. entity and BCA, which will provide decentralized manufacturing services for Galapagos' CAR-T cell therapy candidates across the U.S., close to cancer treatment centers.
BridGene Biosciences has expanded its strategic collaboration with Galapagos NV (NASDAQ: GLPG) to develop a selective oral SMARCA2 PROTAC for precision oncology. The collaboration, which builds on their January 2024 partnership, combines BridGene's PROTAC discovery engine with Galapagos' expertise in selective ATPase small molecules. BridGene is eligible to receive up to $159 million in total payments, including upfront and milestone payments, as well as tiered royalties on net sales. Galapagos will have exclusive rights for further development and commercialization of the preclinical candidate.
This expanded partnership aims to advance drug discovery for challenging oncology targets, leveraging the strengths of both companies to develop precision medicines for cancer patients with critical unmet needs. The collaboration underscores the importance of strategic alliances in advancing drug development efforts and validates BridGene's innovative approach in small molecule drug discovery for hard-to-drug targets.
Adaptimmune and Galapagos have entered a clinical collaboration to evaluate Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer. The trial aims to leverage Galapagos' decentralized manufacturing platform to improve efficacy and durability. Initial trials showed an 80% response rate with partial responses in four out of five patients. Adaptimmune will receive $70M upfront, $30M in R&D funding, and potentially up to $465M in milestone payments, with additional tiered royalties. Galapagos has an option to license uza-cel for global development and commercialization.
Scipher Medicine announced that Galapagos (GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD), following preclinical validation work. This collaboration will trigger a milestone payment to Scipher and allow them to receive additional payments based on future regulatory and sales milestones. The partnership is aimed at developing therapies for unmet needs in IBD using Scipher's Spectra™ platform, which leverages extensive molecular data to enhance drug response rates.
Galapagos NV and Gilead Sciences have announced the halt of the ISABELA Phase 3 clinical studies for ziritaxestat, an investigational autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF). This decision follows the Independent Data Monitoring Committee's review, which indicated that the benefit-risk profile of ziritaxestat no longer supports ongoing trials. The ISABELA program aimed to enroll 1,500 patients, but all trials, including a Phase 2a extension, will be discontinued. Both companies expressed disappointment but remain committed to advancing IPF research.
Galapagos NV (GLPG) announces the completion of Selvita S.A.'s acquisition of Fidelta for €31.2M. This strategic move nearly doubles Selvita's revenues, enhancing its drug discovery services. Fidelta, located in Croatia, employs 181 scientists and has a strong history in inflammation and fibrosis research. The acquisition strengthens Selvita’s position in the European contract research market and allows Fidelta to continue providing services to Galapagos for five years, ensuring ongoing collaboration.
On November 23, 2020, Galapagos NV (GLPG) announced the acquisition of Fidelta d.o.o. by Selvita S.A. for an enterprise value of €31.2M, to be paid in cash. This acquisition is poised to enhance Selvita's position as a leading preclinical contract research organization in Europe, almost doubling its revenues. Fidelta, currently providing drug discovery services, will continue its operations for Galapagos for the next five years. The deal is expected to close on January 4, 2021, and will significantly expand Selvita's integrated drug discovery services.
FAQ
What is the current stock price of Galapagos Nv (GLPG)?
What is the market cap of Galapagos Nv (GLPG)?
